Virtual Library
Start Your Search
Shay Cahal
Author of
-
+
EP1.06 - Mesothelioma (ID 196)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Mesothelioma
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.06-07 - In Vivo Studies of Tumor Treating Fields to Upper Torso in Combination with Chemotherapy Show No Additional Toxicities (ID 1789)
08:00 - 18:00 | Author(s): Shay Cahal
- Abstract
Background
Tumor Treating Fields (TTFields) are low intensity, intermediate frequency alternating electric fields targeting rapidly dividing cells. TTFields (200 kHz) are FDA-approved for the treatment of glioblastoma based on phase 3 studies demonstrating efficacy and a high safety profile. TTFields are currently being tested as a treatment option for other solid tumors in the brain, abdomen, and torso. We evaluated if the safety profile of TTFields is maintained at various frequencies in the upper torso.
Method
TTFields (150 kHz) were applied for 1-4 weeks using the Novo-TTF 100 system to rat and rabbit torso at 2-3 V/cm, which are intensities and frequencies known to be effective for the treatment of NSCLC and mesothelioma. The safety of TTFields in combination with liposomal doxorubicin and cyclophosphamide or paclitaxel was tested in animals. Throughout the treatment course, all animals underwent daily clinical examination by a certified experienced veterinarian and their body weight was determined on a weekly basis. Extensive blood workup, ECG, and temperature measurements were performed in the rabbit experiments. At the end of treatment, animals were euthanized and an experienced independent pathologist performed histological comparative evaluation of all major internal organs.
Result
No changes in the following parameters were observed in activity level, food intake, drinking, stools, motor neurological status, and respiration. Further, no changes in weight were observed between the TTFields treated and relevant control groups. No significant changes were observed in complete blood count and differential between TTFields treated animals and relevant control groups. Histological analysis did not reveal any increase in pathological findings in the TTFields treated animal groups.
Conclusion
These results demonstrate the safety of TTFields application at frequencies of 150 kHz to the torso. No additional toxicities were observed with the combination of TTFields and chemotherapy agents vs chemotherapy agents alone. This work further supports the safety profile of TTFields and offers opportunities for combining TTFields with various chemotherapy agents in lung cancers.
